Since 1985, Cancer Progress has provided pharmaceutical and biotech executives
the opportunity to review and discuss significant contemporary issues in
oncology. During two days of presentations and panels, world-class researchers
and key executives offer incisive overviews and candid
assessments of today’s most important topics. This year, they included:
Targeted therapies promise to
revolutionize cancer treatment. Many of the hottest new clinical and
preclinical candidates will be profiled with perceptive comments and
questions on their promise and challenges.
as predictive and prognostic factors are undergoing rapid technological
advancements and unveiling new clinical applications. Their opportunities
and implications will be integral components of several panel discussions.
Advances in imaging systems provide
non-invasive options for consistent, objective evaluations of responses in
solid tumors – beyond RECIST. How are these new modalities being
incorporated into drug discovery and clinical trials? How are they changing
the way companies are thinking about conducting trials and follow-on
stratification and adaptive designs are increasingly being applied in
oncology clinical trials. What are the implications? How will companies
benefit? What trials currently use this methodology? What’s on the
The conference will examine innovative
business models and emerging challenges which are impacting the industry.
Will the novel risk-sharing alliance between AstraZeneca and Merck become a
trend for the future? How will the reintroduction of Iressa be implemented?
Can collaborations with integrative cancer institutes shorten the path to
commercialization? How might new rules and policy changes impact pricing?
Can companies recapture the expenditures of bringing a drug to market? Will
new regulations stifle innovation?
Unbiased cutting-edge presentations, lively
panel discussions and vigorous audience interactions yield exceptional
new understanding and insights. Networking is a major factor
throughout the meeting during breaks, luncheons, reception and dinner. All
attendees receive a conference handbook and web-access to slides, plus the
annually-updated report "Oncology Drugs in the Pipeline". Participants are
also invited to attend the optional Szent-Gyorgyi Prize Award Dinner
sponsored by the National Foundation for Cancer Research (NFCR). This prize is
awarded each year by the NFCR to a basic science researcher who has made an
extraordinary contribution to cancer research.
Plan now to join us in March 2011
for an unsurpassed learning experience which consistently receives top marks for
quality of information, coverage of issues, and value of professional
Conference Slides (registrants only)